Nkarta Q3 2021 Earnings Report
Key Takeaways
Nkarta reported a net loss of $22.4 million for the third quarter of 2021. As of September 30, 2021, Nkarta had cash, cash equivalents, restricted cash and short-term investments of $259.8 million. The company expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.
Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDS
Successful dosing of NKX019 in patients with B cell malignancies; initial Phase 1 clinical trial data expected in 2022
Nkarta is producing the clinical supply of NKX019 at its recently commissioned in-house cGMP clinical manufacturing facility in South San Francisco, California.
Nkarta entered a lease agreement to establish a new 88,000 square foot combined manufacturing facility and company headquarters.
Nkarta
Nkarta
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into at least the second half of 2023.